Immvira Bioscience, a pre-revenue biotechnology company focused on clinical need-driven development, has filed for a Hong Kong listing under Chapter 18A of the Listing Rules, according to Ming Pao reported.
Citigroup and CICC (3908) are the joint sponsors.
Immvira Bioscience Files Hong Kong Listing Application Under Chapter 18A
2026-07-16 11:07:39
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
Eli Lilly to Buy Atai Beckley for $2.8 Billion
